Fixed-duration acalabrutinib and venetoclax, with or without obinutuzumab, may improve outcomes over chemoimmunotherapy in patients with previously untreated CLL.

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia,” published in the February 2025 issue of New England Journal of Medicine by R. Brown et al. Researchers conducted a ...

In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The fixed-duration treatment of ICP-248 in combination with orelabrutinib will provide deeper remission for treatment-naïve CLL/SLL patients without drug-resistant mutations, bringing hope of ...

The drug has been approved for relapsed/refractory (r/r) CLL/SLL, r/r marginal zone lymphoma and r/r mantle cell lymphoma on China's National Reimbursement Drug List. InnoCare Pharma focuses on ...